



in KYOTO

The Joint Meeting of

The 12th World Congress of International Society for Apheresis

ISFA2019

The 40th Annual Meeting of Japanese Society for Apheresis

JSFA2019

Program & Abstracts

Date : October 17(Thu)-20(Sun), 2019

Venue : Kyoto International Conference Center, Kyoto, Japan

Congress President : Yoshihiro Endo, MD, PhD

Professor, Department of Clinical Nursing, Shiga University of Medical Science
President, ISFA



Dear Friends and Colleagues,

I am pleased to welcome you to the 12th World Congress of International Society for Apheresis (ISFA), in conjunction with the 40th Annual Meeting of Japanese Society for Apheresis (JSFA), which will take place in Kyoto, Japan October 17th - 20th in 2019.

ISFA is the unique international society for apheresis mainly composed of individual members. It was founded in 1996 to disseminate the most up-to-date apheresis technologies and their clinical applications. Almost 500 members from all over the world have joined us today.

ISFA's congress is to be held biennially, and the venue is to be arranged in the region of America, Europe, or Pan-Pacific in rotation. This will be the second ISFA congress held in Kyoto, following the 1st World Congress of ISFA in 1996. It is my profound pleasure and great honor to host ISFA 2019 back again in Kyoto, which reminds us the memorable 1st ISFA Congress.

JSFA had originally started as Japanese Society for Therapeutic Plasmapheresis (the predecessor of JSFA) in 1982. JSFA was established based on it in 1992, and it has evolved into a big society with more than 1,600 members ever since.

Being held at the same time, ISFA 2019 & JSFA 2019 must become a historic meeting. This congress will serve as a springboard again and strongly contribute the remarkable and world-wide advancement of apheresis in both scientific and clinical fields.

You can participate in very active discussions and cutting edge lectures by the world-famous scientists, physician, clinical engineers and nurses. Or you can just look to see how other professionals deal with the clinical cases of apheresis. This congress promises to become a useful opportunity for you to encounter the up-to-date technologies of apheresis.

Kyoto is famous for wonderful historic scenery with traditional architecture and beautiful nature of more than 1200 years. It has 17 UNESCO World Cultural Heritage Sites and over 2,000 temples and shrines.

Many of the tourist cities are easily accessible from Kyoto, because it is located at the main traffic point and at the geographic center of Japan. You can get any places in Japan by trains or aircrafts within a couple of hours.

I am very excited to see you from every part of the world and to welcome you to FANTASTIC KYOTO.

Sincerely,

Yoshihiro Endo, MD, PhD.
Congress President
International Society for Apheresis (ISFA)
Japanese Society for Apheresis (JSFA)

Oct 18th Room A

9:00-10:30 **Workshop**

E-ISFA Workshop Kyoto

Chairs: Bernd Hohenstein *(Nephrological Center Villingen-Schwenningen, Germany)*
Wolfgang Ramlow *(Apheresis Center Rostock, Germany)*

WS-01 Update on vasculitis treatment including plasma exchange

Wladimir Szpirt *(Rigshospitale, Copenhagen, Denmark)*

WS-02 Lipoprotein(a): Delicate Risk Factor and Prime Target for Apheresis

Wolfgang Ramlow *(Apheresis Center Rostock, Germany)*

WS-03 Why should immunoadsorption be a therapy of continuing interest?

Bernd Hohenstein *(Nephrological Center Villingen-Schwenningen, Germany)*

10:45-12:15 **Symposium 1**

Current State of CAR-T Therapies in the World

Chair: Chisa Yamada *(Department of Pathology, University of Michigan, USA)*

SY1-01 Current Status of CAR-T Therapy in the United States

Nicole Aqui *(Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA)*

SY1-03 Basic and clinical studies of CAR-T cell therapy in Japan

Keiya Ozawa *(Division of Immuno-Gene & Cell Therapy (Takara Bio), Jichi Medical University, Tochigi, Japan)*

12:30-13:30 **Luncheon Seminar 1**

Sponsored by Novartis Pharma K.K.

Standard of Apheresis/Cell processing Site for CAR-T therapy

Chair: Peter Holman *(Global Apheresis Integration, Novartis Pharmaceuticals Corp., Germany)*

LS1-01 Institutional preparation for CAR-T Cell Therapy and Apheresis

Peter Holman *(Global Apheresis Integration, Novartis Pharmaceuticals Corp., Germany)*

LS1-02 How to establish the management system for CAR-T therapy in Japan

Masafumi Onodera *(Gene and Cell Therapy Promotion Center, National Center for Child Health and Development)*



14:30-15:00 Special Lecture 1

Memorial Seminar for the late Prof. Akira Yamamoto

- Chairs:** Hidenori Matsuo (*Neurology, National Hospital Organization, Nagasaki National Hospital, Japan*)
 Tadao Akizawa (*Division of Nephrology, Department of Medicine, Showa University School of Medicine, Japan*)

SL1-01 Remembrance of Dr. Akira Yamamoto

Mariko Harada-Shiba (*Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Japan*)

SL1-02 In Memory of Prof. Akira Yamamoto

Yoshihiro Endo (*Department of Clinical Nursing, Shiga University of Medical Science, Japan*)

15:30-17:00 Symposium 2

Registry of lipoprotein apheresis

- Chairs:** Patrick M. Moriarty (*University of Kansas Medical Center, USA*)
 Mariko Harada-Shiba (*Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Japan*)

SY2-01 North American Lipoprotein Apheresis Registry (NALAR): Data collection design and rationale

Patrick M. Moriarty (*University of Kansas Medical Center, USA*)

SY2-02 Registry of homozygous familial hypercholesterolemia

Mariko Harada-Shiba (*Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Japan*)

SY2-03 Current insights into the German Lipoprotein Apheresis Registry (GLAR), more than 7 years on

Volker J. J. Schettler (*Center of Nephrology Goettingen GbR, Goettingen, Germany*)

SY2-04 LDL apheresis in Heterozygous Familial Hypercholesterolemia : data from the French Registry of Familial hypercholesterolemia (REFERCHOL)

Antonio Gallo (*Cardiovascular Prevention Unit, University Hospital Pitie Salpetriere, France*)

17:05-18:05 Evening Seminar 1

Sponsored by AbbVie

Treatment of inflammatory bowel disease in Europe

- Chair:** Taku Kobayashi (*Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan*)

ES1-01 Treatment of inflammatory bowel disease in Europe

Rodolfo Sacco (*Gastroenterology and Digestive Endoscopy Unit, University of Foggia Medical School, Italy*)

Program
Friday, Oct.
18, 2019

Program
Saturday, Oct.
19, 2019

Program
Sunday, Oct.
20, 2019

Special Lecture

Symposium

Guideline
Session

Apheresis
Manual Lecture

Technical Talk

E-SFA
Work Shop

State of the Art
in the World

English
Oral Session

Japanese
Oral Session

Poster
Presentation

Sponsored
Seminar



18:10-18:40 Special Lecture 2

Commemorating Seminar, JSFA to be the member society of the Japanese Association of Medical Science

- Chairs:** Hiroshi Tsuda (*Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan*)
 Hidenori Matsuo (*Neurology, National Hospital Organization, Nagasaki National Hospital, Japan*)

SL2-01 Tetsuzo Agishi (*Professor emeritus, Tokyo Women's University, Japan*)

SL2-02 Michio Mineshima (*Department of Clinical Engineering, Tokyo Women's Medical University, Tokyo, Japan*)

Room D

9:00-10:35 Symposium 3 — IBD 1

Apheresis therapy for inflammatory bowel disease -Past, Present, Future-1

- Chairs:** Yamin Lai (*Peking Union Medical College Hospital (Dongdan campus), No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing,China*)
 Makoto Naganuma (*Division of Gastroenterology and Hepatology, Keio University School of Medicine, Japan*)

SY3-01 Leukocytapheresis as an Adjunct to Medication for Inflammatory Bowel Disease

Koji Sawada (*Director of Dojima General & Gastroenterology Clinic, Japan*)

SY3-02 Granulomonocytoapheresis as therapeutic option of IBD in Europe

Rodolfo Sacco (*Gastroenterology and Digestive Endoscopy Unit, University of Foggia Medical School, Italy*)

SY3-03 Adsorptive Granulocyte and Monocyte Apheresis in the Treatment of Inflammatory Bowel disease : The First Multicenter Study In China

Yamin Lai (*Peking Union Medical College Hospital (Dongdan campus), No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing,China*)

SY3-04 Real-world experiences of cytapheresis therapy for ulcerative colitis; results from large-scale multicenter observational studies

Taku Kobayashi (*Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan*)

SY3-05 Factors affecting clinical remission in patients with ulcerative colitis treated with cytapheresis therapy

Shigeki Bamba (*Division of Clinical Nutrition, Shiga University of Medical Science, Japan*)

10:45-12:15 Symposium 4 — IBD 2

Apheresis therapy for inflammatory bowel disease -Past, Present, Future-2

- Chairs:** Yamin Lai (*Peking Union Medical College Hospital (Dongdan campus), No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing,China*)
 Makoto Naganuma (*Division of Gastroenterology and Hepatology, Keio University School of Medicine, Japan*)

SY4-01 A novel leucocyte apheresis adsorption system in refractory active ulcerative colitis

Wolfgang Kruis (*Evangelisches Krankenhaus Köln Kalk (Formerly active as chief physician), Germany*)



- SY4-02 Safety and efficacy of single needle leucocyte apheresis for ulcerative colitis: A retrospective analysis**
 Youichiro Shindo *(Division of Gastroenterology Department of Medicine, Kurume University School of Medicine, Kurume, Japan)*
- SY4-03 The efficacy of combination therapy of intensive GMA with biologics or a JAK inhibitor for refractory inflammatory bowel disease**
 Satoshi Tanida *(Department of Gastroenterology and Metabolism, Japan)*
- SY4-04 Efficacy apheresis as maintenance therapy for patients with ulcerative colitis in a prospective multicentre randomised controlled trial**
 Makoto Naganuma *(Division of Gastroenterology and Hepatology, Keio University School of Medicine, Japan)*

12:30-13:30 Luncheon Seminar 2

Sponsored by JIMRO

Vascular access practices for GMA treatment

Chair: Ken Yamaji *(Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Japan)*

LS2-01 Vascular Punctures for GMA treatment

Hisashi Matono *(Department of medical engineer, Wakakusa-Daiichi Hospital, Japan)*

LS2-02 Tips for ensuring vascular access and maintaining extracorporeal circulation in pediatric blood purification therapy

Mariko Sawada *(Department of Pediatrics, Kurashiki Central Hospital, Japan)*

15:30-17:00 Symposium 5 — Dermatology

Advancement of Apheresis in Dermatology

Chairs: Chisa Yamada *(Transfusion Medicine, Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA)*
 Shigaku Ikeda *(Department of Dermatology, Juntendo University School of Medicine, Japan)*

SY5-01 Granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis

Mariko Seishima *(Department of Dermatology, Gifu University Graduate School of Medicine, Japan)*

SY5-02 Granulocyte and monocyte adsorption apheresis for psoriatic arthritis

Takuro Kanekura *(Department of Dermatology, Kagoshima University, Kagoshima, Japan)*

SY5-03 Extracorporeal Photopheresis Treatment for Dermatological Diseases

Chisa Yamada *(Transfusion Medicine, Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA)*

SY5-04 Autologous Hematopoietic Stem Cell Transplantation for Treatment of Severe Systemic Sclerosis

Mark Wener *(University of Washington, Department of Laboratory Medicine & Division of Rheumatology, USA)*

Program
Friday, Oct.
18, 2019

Program
Saturday, Oct.
19, 2019

Program
Sunday, Oct.
20, 2019

Special Lecture

Symposium

Guideline
Session

Apheresis
Manual Lecture

Technical Talk

E-SFA
Work Shop

State of the Art
in the World

English
Oral Session

Japanese
Oral Session

Poster
Presentation

Sponsored
Seminar



17:05-18:05 Evening Seminar 2

Sponsored by Asahi KASEI Medical

Latest findings of cell-free and concentrated ascites reinfusion therapy (CART) using blood purification equipment “Plasauto μ ”

Chair: Motoki Yonekawa (*Sapporo Hokuyū Hospital, Japan*)

ES2-01 How to handle CART mode on blood purification equipment “Plasauto μ ”

Hiroyuki Miyakawa (*Japanese Red Cross Medical Center, Japan*)

ES2-02 Comparison between the internal and external pressure filtration method of cell-free and concentrated ascites reinfusion therapy and Plasauto μ usability

Midori Hasegawa (*Fujita Health University, Japan*)

Room B-1

9:00-10:30 Symposium 6 — PDF SESSION I

Chairs: Alexey A. Sokolov

(*The Department of Anesthesiology and Reanimatology, North-Western State Medical University named after I.I.Mechnikov, St.Petersburg, Russia*)

Yutaka Eguchi

(*Department of Critical and Intensive Care Medicine, Shiga University of Medical Science, Japan*)

SY6-01 The improvement of acute kidney injury by plasmadialfiltration on sepsis animal model

You Li (*Dept. of Nephrology, Huashan Hospital, Fudan University, Shanghai, China*)

SY6-02 Plasma adiponectin levels in acute liver failure patients treated with plasma filtration with dialysis and plasma exchange

Yoshitaka Uji (*Department of Emergency and Gastroenterological Surgery, Shin-Koga Hospital, Fukuoka, Japan*)

SY6-03 PDF procedure induce IL-10; a case report

Yutaka Eguchi (*Department of Critical and Intensive Care Medicine, Shiga University of Medical Science, Japan*)

SY6-04 Utility of the novel artificial liver support combination therapy, PDF with high flow-volume CHDF

Kota Kamizato (*Department of Anesthesiology and Intensive Care Medicine, University of the Ryukyus, Okinawa, Japan*)

SY6-05 High flow-volume plasma filtration with dialysis and plasma exchange with dialysis

Hajime Nakae (*Department of Emergency and Critical Care Medicine, Akita University Graduate School of Medicine, Japan*)

SY6-06 Continuous plasmfiltration with dialysis (CPDF)

Takumi Taniguchi (*Department of Anesthesiology and Intensive Care Medicine, Kanazawa University, Kanazawa, Japan*)


10:45- 12:00 Symposium 7 — PDF Session II

- Chairs:** Xue Jun (*Dept. of Nephrology, Huashan Hospital, Fudan University, Shanghai, China*)
 Hajime Nakae (*Department of Emergency and Critical Care Medicine, Akita University Graduate School of Medicine, Japan*)

SY7-01 Comparison of selective plasma exchange, plasma diafiltration, MARS and Prometheus systems in treatment of liver failure

Alexey A. Sokolov (*The Department of Anesthesiology and Reanimatology, North-Western State Medical University named after I.I.Mechnikov, St.Petersburg, Russia*)

SY7-02 Safety Management in Plasma Diafiltration

Maki Kagitani (*Blood Purification Center, Osaka Medical College, Japan*)

SY7-03 Artificial liver support for liver transplant recipients during perioperative period

Hironori Hayashi (*Department of Surgery, Toyama Prefectural Central Hospital, Japan*)

SY7-04 Multicenter Study of Plasma filtration with dialysis (PDF) in Patients with Acute Liver Failure

Yutaka Eguchi (*Department of Critical and Intensive Care Medicine, Shiga University of Medical Science, Japan*)

SY7-05 Clinical application and effect analysis of plasma diafiltration (PDF) in patients with liver failure

Yi Tian (*Dep.Infectious disease, the Second Xiangya Hospital, Central South University, Changsha, China*)

12:30-13:30 Luncheon Seminar 3
Sponsored by NIKKISO

- Chair:** Wolfgang Krüis (*The hospital Evangelisches Krankenhaus Köln Kalk, Germany*)

LS3-01 Adsorption mechanism of Immunopure

Grit Waitz (*Nephrocare Rostock GmbH Medizinisches Versorgungszentrum Südstadt, Germany*)

- Chair:** Grit Waitz (*Nephrocare Rostock GmbH Medizinisches Versorgungszentrum Südstadt, Germany*)

LS3-02 Apheresis for treatment of active ulcerative colitis: evidence and developments

Wolfgang Krüis (*The hospital Evangelisches Krankenhaus Köln Kalk, Germany*)

16:00-17:00 Apheresis Manual Lecture
AM-01 Acute blood purification therapy in critical care

Takahisa Tabata

 Program
 Friday, Oct.
 18, 2019

 Program
 Saturday, Oct.
 19, 2019

 Program
 Sunday, Oct.
 20, 2019

Special Lecture

Symposium

 Guideline
 Session

 Apheresis
 Manual Lecture

Technical Talk

 E-SFA
 Work Shop

 State of the Art
 in the World

 English
 Oral Session

 Japanese
 Oral Session

 Poster
 Presentation

 Sponsored
 Seminar


Room B-2

9:00-10:30 State of the Art 1 — Critical Care Medicine

Chair: Paul S. Malchesky (ICAOT, USA)

- SA1-01 Current status of plasma exchange in critical ill patients in Vietnam**
Hien_Thi Thu Huynh (*Cho Ray Hospital, Ho Chi Minh, Vietnam*)
- SA1-03 Results from the CAMI1 Study: Selective CRP apheresis as a new treatment option in acute myocardial infarction**
Ahmed Sheriff (*Charite Universitaetsmedizin, Medizinische Klinik Gastroenterologie/ Infektiologie/ Rheumatologie, Germany*)
- SA1-04 The improving effects of lipoprotein apheresis on cardiac vascular ultrasonic parameters**
Dongliang Zhang (*The Blood Purification Center of Nephrology Department, Peking University International Hospital, China*)
- SA1-05 After EUPHRATIS Is LPS Apheresis for Sepsis obsolete? In-vitro investigation for a new concept of Endotoxin adsorption**
Mandry Peter (*B. Braun Avitum Saxonia GmbH, Germany*)

10:45-12:15 State of the Art 2 — Nephrology/Others

Chair: Dusit Lumlertgul (Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand)

- SA2-01 Severe Nephrotic Syndrome with Hyperthyroidism and Acute Renal Failure Treatment with Plasmapheresis and Immunosuppressive drug: Tacrolimus**
Dusit Lumlertgul (*Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand*)
- SA2-02 Effects of LDL-Apheresis in Adult Refractory Nephrotic Syndrome and Its Reproducibility**
Hideki Takizawa (*The Department of Nephrology, Teine Keijinkai Hospital, Sapporo, Japan*)
- SA2-03 Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of Full AUC0-12**
Sudarat Piyasiridej (*Nephrology unit, Department of Medicine, Chulalongorn University, Bangkok, Thailand*)
- SA2-04 Immunoadsorption treatment of recurrent primary focal segmental glomerulosclerosis: A single center experience**
Hamza Naciri Bennani (*Department of Nephrology, Hemodialysis, Apheresis and Renal Transplantation, CHU Grenoble-Alpes, Grenoble, France*)
- SA2-05 Apheresis therapy for steroid-resistant idiopathic nephrotic syndrome: Report on three cases**
Hamza Naciri Bennani (*Department of Nephrology, Hemodialysis, Apheresis and Renal Transplantation, CHU Grenoble-Alpes, Grenoble, France*)
- SA2-06 Rationale and Study Design of LDL apheresis-mediated Endothelial activation Therapy to Severe-Peripheral Artery Disease study (LETS-PAD study)**
Eiko Ueda (*Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan*)


15:30-17:00 English Oral 1 — Critical Care Medicine

Chair: Hajime Nakae (*Department of Emergency and Critical Care Medicine, Akita University, Japan*)

EO1-01 Nafamostat mesylate inhibition of LZD metabolism via its antioxidant effects

Naohide Kuriyama (*Department of Anesthesiology & Critical Care Medicine, Fujita Health University, Toyoake, Japan*)

EO1-02 The mechanism of the decrease in cardiac output measurement by transpulmonary thermodilution has been elucidated

Tomoyuki Nakamura (*Department of Anesthesiology and Critical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan*)

EO1-03 Treatment of chronic Heavy Metal Intoxication by Plasmapheresis, Promise or Illusion?

Gerhard Puetz (*Institute of Clinical Chemistry and Laboratory Medicine, Faculty of Medicine, University of Freiburg, Freiburg, Germany*)

EO1-04 A Case series -Use of Therapeutic Plasma Exchange (TPE) in the management of Patients with Snake bite

Indika de Alwis (*Regional Blood Centre, T H Ratnapura, Sri Lanka*)

EO1-05 Biocompatibility and efficacy of self-anticoagulative chitosan- κ -carrageenan composite hydrogel for simultaneous endotoxin adsorption and bacteria capture in septic blood

Yupei Li (*Department of Nephrology, West China Hospital, Sichuan University, Chengdu, China*)

EO1-06 Lactate predicts the 28-day survival rate in patients with septic shock treated with the combination of PMX-DHP and rTM

Masafumi Yamato (*Department of Nephrology, National Hospital Organization, Osaka National Hospital, Osaka, Japan*)

Room E
9:00-10:00 Japanese Oral 1 — Ascites/CART

Chair: Yuji Kamijo (*Shinshu University School of Medicine, Japan*)

JO1-01 Investigation of washing volume for Back-filtration cleaning in CART
JO1-02 Examination of the optimal ascites concentration rate when using blood purification equipment “Plasauto μ CART mode”
JO1-03 Evaluation of the dedicated equipment, Plasauto μ , for CART (Cell-free and Concentrated Ascites Reinfusion Therapy)
JO1-04 Evaluation of safety in CART using blood purification equipment Plasauto μ

 Program
Friday, Oct.
18, 2019

 Program
Saturday, Oct.
19, 2019

 Program
Sunday, Oct.
20, 2019

Special Lecture

Symposium

 Guideline
Session

 Apheresis
Manual Lecture

Technical Talk

 E-ISFA
Work Shop

 State of the Art
in the World

 English
Oral Session

 Japanese
Oral Session

 Poster
Presentation

 Sponsored
Seminar


10:45-12:15 State of the Art 3 — LDL

Chair: Mariko Harada-Shiba (*Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Japan*)

SA3-02 Establishing Low-Density Lipoprotein Apheresis Tolerability in Patients with Prior Anaphylactoid Reactions to Lipid Apheresis using Magnesium Sulfate

Ethan Alexander (*University of Kansas School of Medicine, Department of Clinical Pharmacology, Kansas City, Kansas, USA*)

SA3-03 Impact of PCSK9 inhibitors on LDL apheresis

Samir Saheb (*Departement of Endocrinology and Metabolism, Sorbonne University, Paris, France*)

SA3-04 Beyond cholesterol, pleotropic effects of lipoprotein apheresis

Volker J.J. Schettler (*Center of Nephrology Goettingen, Goettingen, Germany*)

SA3-05 Apheresis in preeclampsia – Lipids, angiogenetic factors or else? (The APPROVE project, a controlled multi-center apheresis trial)

Karl Winkler (*Institute of Clinical Chemistry and Laboratory Medicine, Faculty of Medicine, University of Freiburg, Germany*)

15:30-16:00 Japanese Oral 2 — IBD

Chair: Yoko Yokoyama (*Department of Inflammatory Bowel Disease, Division of Internal Medicine, Hyogo College of Medicine, Japan*)

JO2-01 Effect of cellulose acetate beads on the release of interleukin-13 at different temperatures

JO2-02 Examination of the therapeutic effect in our hospital GMA LCAP (CAP) therapy

Room D Foyer

10:30-11:50 Poster Presentation 1 — Hepatology/others

Chair: Kazuaki Inoue (*Gastroenterology, Showa University Fujigaoka Hospital, Japan*)

PP1-04 Fructus Psoraleae-induced severe liver injury and treatment with two artificial liver support systems: A case series study

Zhongyang Xie (*State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, China*)

15:00-16:10 Poster Presentation 2 — Ascites/CART/IBD

Chair: Yuji Kamijo (*Shinshu University School of Medicine, Japan*)

PP2-01 Biochemical Evaluation of Processed Ascites in Patients Undergoing Cell-Free and Concentrated Ascites Reinfusion Therapy

Hironori Nakamura (*Department of Nephrology, Shinonoi General Hospital, Nagano, Japan*)



- PP2-02 **Suppression of inflammation during cell-free concentrated ascites reinfusion therapy (CART) using a blood purification device**
- PP2-03 **The washing using the normal saline to drain to the two directions for the clogged filtration filter is effective**
- PP2-04 **Development and clinical evaluation of an ascites filtration and concentration equipment by interprofessional collaboration**
- PP2-05 **Clinical factors associated with relapse of ulcerative colitis after granulocyte-monocyte adsorption**
- PP2-06 **Efficacy and safety of granulocyte and monocyte adsorptive apheresis in elderly vs. non-elderly patients with ulcerative colitis**
- PP2-07 **Development of a tube holder-type circuit set for cell free and concentrated ascites reinfusion therapy (CART)**

Program
Friday, Oct.
18, 2019

Program
Saturday, Oct.
19, 2019

Program
Sunday, Oct.
20, 2019

Special Lecture

Symposium

Guideline
Session

Apheresis
Manual Lecture

Technical Talk

E-ISFA
Work Shop

State of the Art
in the World


English
Oral Session

Japanese
Oral Session

Poster
Presentation

Sponsored
Seminar





Program

Saturday, October 19, 2019

Program
Friday, Oct.
18, 2019

Program
Saturday, Oct.
19, 2019

Program
Sunday, Oct.
20, 2019

Special Lecture

Symposium

Guideline
Session

Apheresis
Manual Lecture

Technical Talk

E-ISFA
Work Shop

State of the Art
in the World

English
Oral Session

Japanese
Oral Session

Poster
Presentation

Sponsored
Seminar

Oct 19th Room A

9:00-10:30 Symposium 8 — Critical Care Medicine

Chairs: Xiuming Xi *(Past President of CSCCM, China)*
 Takeshi Moriguchi *(Department of Emergency and Critical Care Medicine, University of Yamanashi School of Medicine, Yamanashi, Japan)*

SY8-01 Dose of CRRT in AKI: The Other Way Around

Bin Du *(Medical ICU, Peking Union Medical College Hospital, China)*

SY8-02 Apheresis for Sepsis

Takeshi Moriguchi *(Department of Emergency and Critical Care Medicine, University of Yamanashi School of Medicine, Yamanashi, Japan)*

SY8-03 The application of the column adsorbing LAP positive cells to therapy of sepsis-induced immune paralysis

Kazuo Teramoto *(Department of Pathology, Shiga University of Medical Science, Japan)*

SY8-04 Early Prediction of Acute Kidney Injury in ICU

Haibo Qiu *(Dept. of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, China)*

10:45-12:15 Symposium 9 — PMX

Update report, PMX on sepsis

Chairs: Tohru Tani *(Department of Research and Development for Innovative Medical Devices and Systems, Shiga University of Medical Science, Japan)*
 Hisataka Shoji *(Toray Medical Co., Japan)*

SY9-01 Impact of timing of polymyxin B immobilized fiber column direct hemoperfusion on outcome in patients with septic shock

Tomoki Tanaka *(Shiga University of Medical Science Emergency and Intensive Care Unit, Shiga, Japan)*

SY9-02 Blood purification for septic shock patients

Toshiaki Ikeda *(Division of Critical Care Medicine Tokyo Medical University, Hachioji Medical Center, Japan)*

SY9-03 Role of Rescue therapy using Polymyxin B Hemoperfusion in immunocompromised hosts with refractory septic shock

Sang-Bum Hong *(Department of Pulmonary and Critical Care Medicine, Asan Medical Center in Seoul, Univ. of Ulsan, College of Medicine, Korea)*

SY9-04 The case for using PMX in critically ill patients – Don't through out the baby with the bath water

Sean M. Bagshaw *(Critical Care Medicine, University of Alberta, Canada)*

12:30-13:30 Luncheon Seminar 4

*Simultaneous interpretation is available.

Sponsored by Asahi KASEI Medical

Pathogenic Antibodies and Lipoproteins – Current Trends in Therapeutic Apheresis

Chair: Hidenori Matsuo *(National Hospital Organization, Nagasaki National Hospital, Japan)*



LS4-01 Pathogenic Antibodies and Lipoproteins – Current Trends in Therapeutic Apheresis

Reinhard Klingel *(Apheresis Research Institute, Cologne and 1st Department of Internal Medicine, University of Mainz, Germany)*

13:40-15:30 Guideline Session 1

Chair: Hidenori Matsuo *(National Hospital Organization, Nagasaki National Hospital, Japan)*

GS1-01 The JSFA clinical practice guideline for Therapeutic Apheresis

Takaya Abe *(Department of Urology, Iwate Medical University, Iwate, Japan)*

GS1-02 The Chapter for the Kidney Diseases, the Japanese Society for Apheresis Guideline

Norio Hanafusa *(Department of Blood Purification, Tokyo Women's Medical University, Tokyo, Japan)*

GS1-03 Clinical practice guidelines for therapeutic apheresis in emergency and critical care

Hajime Nakae *(Department of Emergency and Critical Care Medicine, Akita University Graduate School of Medicine, Japan)*

GS1-04 The apheresis guidelines for digestive diseases

Kazuaki Inoue *(Division of Gastroenterology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan)*

Tomoki Furuya *(Department of Emergency and Critical Care Medicine, Akita University Graduate School of Medicine, Japan)*

Yoko Yokoyama *(Department of Internal Medicine, Division of Inflammatory Bowel Disease, Hyogo College of Medicine, Japan)*

GS1-05 Guideline of Apheresis in Cardiovascular Disease

Mariko Harada-Shiba *(National Cerebral and Cardiovascular Center Research Institute, Japan)*

GS1-06 Guidelines on the use of therapeutic apheresis in pulmonary diseases: the potential treatment with direct hemoperfusion with polymyxin B-immobilized fiber column (PMX-DHP) for diffuse alveolar damage (DAD)

Shinji Abe *(Department of Respiratory Medicine, Tokyo Medical University, Japan)*

15:30-17:00 Guideline Session 2

Chairs: Hidenori Matsuo *(National Hospital Organization, Nagasaki National Hospital, Japan)*

GS2-01 Standardization of apheresis technologies

Michio Mineshima *(Department of Clinical Engineering, Tokyo Women's Medical University, Tokyo, Japan)*

GS2-02 Apheresis guideline in Japan for management and treatment of pemphigus, bullous pemphigoid and toxic epidermal necrolysis

Mariko Seishima *(Department of Dermatology, Gifu University Graduate School of Medicine, Japan)*

GS2-03 Japanese apheresis guidelines for the management and treatment of generalized pustular psoriasis, pustulosis palmoplantaris and psoriasis arthropathica

Miho Hatanaka *(Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan)*

Program
Friday, Oct.
18, 2019

Program
Saturday, Oct.
19, 2019

Program
Sunday, Oct.
20, 2019

Special Lecture

Symposium

Guideline
Session

Apheresis
Manual Lecture

Technical Talk

E-ISFA
Work Shop

State of the Art
in the World

English
Oral Session

Japanese
Oral Session

Poster
Presentation

Sponsored
Seminar



GS2-04 JSFA guidelines for hematological disorders

Yasunori Ueda *(Department of Hematology/Oncology, Transfusion and Hemapheresis Center Kurashiki Central Hospital Okayama, Japan)*

GS2-05 JSFA Guidelines 2020 for Neurological Diseases

Kyoichi Nomura *(Department of Neurology, Saitama Medical Center, Saitama Medical University, Japan)*

GS2-06 Description of new guidelines for therapeutic apheresis in the field of rheumatic disease

Makio Kusaoi *(Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan)*

GS2-07 American Society for Apheresis (ASFA) Guidelines for Apheresis

Bruce Sachais *(New York Blood Center, USA)*

Nicole Aquí

Room D

9:00-10:30 Symposium 10 — LDL

Lowering Lp(a)

Chairs: Wolfgang Ramlow *(Apheresis Center Rostock, Germany)*

Beate Jaeger

Atsushi Nohara *(Clinical Genetics, Ishikawa Prefectural Central Hospital, Japan)*

SY10-01 Lipoprotein(a)-Risk Marker and Therapeutic Target

Reinhard Klingel *(Apheresis Research Institute, Cologne and 1st Department of Internal Medicine, University of Mainz, Germany)*

SY10-02 Beate Jaeger

SY10-03 Antisense and RNA interference drug therapy for the reduction of Lp(a) levels

Patrick M. Moriarty *(University of Kansas Medical Center, USA)*

SY10-04 Effect of PCSK9i on Lp(a)

Atsushi Nohara *(Clinical Genetics, Ishikawa Prefectural Central Hospital, Japan)*

10:45-12:15 Symposium 11 — LDL

Position of Lipoprotein Apheresis after Recent Development of Lipid Lowering Drugs

Chairs: Patrick M. Moriarty *(University of Kansas Medical Center Kansas City, KS, USA)*

Mariko Harada-Shiba *(National Cerebral and Cardiovascular Center Research Institute, Japan)*

SY11-01 Treatment of FH in Japan

Hisashi Makino *(The Department of Diabetes and Lipid Metabolism, National Cerebral and Cardiovascular Center, Osaka, Japan)*

SY11-02 Treatment of Familial Hypercholesterolemia in the United States

P. Barton Duell *(Oregon Health and Science University Portland, OR, USA)*

SY11-03 Characteristics of dyslipidemic high-risk cardiovascular patients and how to identify them in clinical routine

Wolfgang Ramlow *(Apheresis Center Rostock, Germany)*



SY11-04 Characterization of patients being treated with lipoprotein apheresis (LA) at the Dresden LA center

Ulrich A. Julius *(Department of Internal Medicine III, University Hospital at the Technische Universität Dresden, Germany)*

12:30-13:30 Luncheon Seminar 5

Sponsored by Kaneka Medix Corp.

Chair: Norio Hanafusa *(Department of Blood Purification, Tokyo Women's Medical University, Tokyo, Japan)*

LS5-01 Safety management in CART using pump for the driving force

LS5-02 What is highly effective CART?

15:30-17:00 Symposium 12 — CART/Ascites

CART, Its Current Status and Prospect for the Future Leaps

Chairs: Yuji Kamijo *(Department of Nephrology, Shinshu University School of Medicine, Japan)*
 Norio Hanafusa *(Department of Blood Purification, Tokyo Women's Medical University, Tokyo, Japan)*

SY12-01 Verification of serum albumin elevating effect of cell-free and concentrated ascites reinfusion therapy for ascites patients

Yosuke Yamada *(Department of Nephrology, Shinshu University School of Medicine, Nagano, Japan)*

SY12-02 Characteristics and methods of the cell-free and concentrated ascites reinfusion therapy (CART) procedure in Japan

Atsushi Ohkubo *(Medical Engineering Center, Medical Hospital of Tokyo Medical and Dental University, Japan)*

SY12-03 Cell-free and Concentrated Ascites Reinfusion Therapy (CART) against malignancy-related ascites

Tetsuya Ito *(Department of Palliative Care, Japanese Red Cross Medical Center, Tokyo, Japan)*

SY12-04 Safety and quality control for filtered and concentrated ascites reinfusion therapy

Taiju Utsugisawa *(Department of Transfusion Medicine and Cell Processing, Tokyo Women's Medical University, Tokyo, Japan)*

17:05-18:05 Evening Seminar 3

Sponsored by Japan Blood Products Organization

Chair: Takafumi Ito *(Division of Nephrology, Shimane University Hospital, Japan)*

ES3-01 Appropriate diluted albumin solution as replacement fluids in PE and SePE

ES3-02 Clinical management of albumin replacement in selective plasma exchange

Program
Friday, Oct.
18, 2019

Program
Saturday, Oct.
19, 2019

Program
Sunday, Oct.
20, 2019

Special Lecture

Symposium

Guideline
Session

Apheresis
Manual Lecture

Technical Talk

E-ISFA
Work Shop

State of the Art
in the World

English
Oral Session

Japanese
Oral Session

Poster
Presentation

Sponsored
Seminar



Room B-1

9:00-10:30 Symposium 13 — Hematology/Transfusion

Hemapheresis and cellular therapy-state of the art and clinical applications-1

Chairs: Yasunori Ueda (*Kurashiki Central Hospital, Japan*)

SY13-01 Overview of Cellular Therapy and the Critical Role for Apheresis Professionals

Bruce Sachais (*New York Blood Center, USA*)

Nicole Aquí

SY13-02 Cellular Collections for Immunotherapy, Perspective from a Large Academic Center

Nicole Aquí (*Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA*)

SY13-03 Impact of Growing Leukapheresis Indications: Two Perspectives from a Hemapheresis Practitioner

Chrissy Anderson (*Apheresis Operations, Bluebird Bio, Inc., USA*)

SY13-04 Recent advances in diagnosis and treatment of light-chain (AL) amyloidosis

Nobuhiro Tsukada (*Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan*)

10:45-12:15 Symposium 14 — Hematology/Transfusion

Hemapheresis and cellular therapy-state of the art and clinical applications-2

Chairs: Yasunori Ueda (*Kurashiki Central Hospital, Japan*)

SY14-01 Autotransplantation for POEMS syndrome

Masahiro Takeuchi (*Department of Hematology, Chiba University Hospital, Chiba, Japan*)

SY14-02 Update on granulocyte transfusions, including granulocytapheresis and clinical effectiveness

Satoshi Yoshihara (*Department of Transfusion Medicine and Cellular Therapy, Japan*)

SY14-03 Plasmapheresis for the treatment of acquired thrombotic thrombocytopenic purpura

Yasunori Ueda (*Department of Hematology / Oncology, Transfusion and Hemapheresis Center Kurashiki Central Hospital Okayama, Japan*)

SY14-04 Atypical hemolytic uremic syndrome

Akira Ashida (*Department of Pediatrics, Osaka Medical College, Japan*)

12:30-13:30 Luncheon Seminar 6

Sponsored by Recordati Rare Diseases Japan K.K.

Updates on familial hypercholesterolemia (FH) including HoFH

~Treatment with LDL-Apheresis and MTP Inhibitor~

Chair: Mariko Harada-Shiba (*National Cerebral and Cardiovascular Center Research Institute, Japan*)



- LS6-01 Treatment efficiency of uncontrolled familial hypercholesterolemia with lomitapide and apheresis-**
Kyoko Inagaki (Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Nippon Medical School, Japan)
- LS6-02 Synergistic effect of Lomitapide and PCSK9 inhibitor on familial hypercholesterolemia homozygote**
Hiromi Tasaki (Cardiovascular medicine, JR Kyushu Hospital, Japan)

15:30-17:00 Symposium 15 — Nephrology

Apheresis for kidney disease

- Chairs:** Andre Kaplan (University of Connecticut, USA)
Takafumi Ito (Division of Nephrology, Shimane University Hospital, Japan)

SY15-01 Therapeutic Apheresis in the Field of Nephrology - Future Direction and Missions of Nephrologists

Norio Hanafusa (Department of Blood Purification, Tokyo Women's Medical University, Tokyo, Japan)

SY15-02 Apheresis for nephrotic syndrome

Kengo Furuichi (Department of Nephrology, Kanazawa Medical University, Uchinada, Japan)

SY15-03 Apheresis for Focal Segmental Glomerulosclerosis

Andre A. Kaplan (University of Connecticut Health Center, Farmington, CT, USA)

SY15-04 Current status of Apheresis in the practice of Rapidly Progressive Glomerulonephritis in Japan

Shuzo Kaneko (The department of Nephrology, University of Tsukuba, Ibaraki, Japan)

SY15-05 Efficacy of selective plasma exchange at pre-transplant desensitization of ABO-incompatible kidney transplantation

Toshihide Naganuma (Department of Urology, Osaka City University, Osaka, Japan)

Room B-2

9:00-10:00 English Oral 2 — Nephrology/others

- Chair:** Eriko Kinugasa (Showa University Northern Yokohama Hospital, Japan)

EO2-01 Comparing the Outcomes of Desensitization for ABO Incompatible and HLA Incompatible Kidney Transplantation

Natavudh Townamchai (Division of Nephrology, Department of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand)

EO2-02 Clinical outcome of the apheresis therapy for acute antibody-mediated rejection after kidney transplantation in our institute

Yasushi Mochizuki (Division of Blood Purification, Nagasaki University Hospital, Japan)

EO2-03 Cost analysis of therapeutic plasma exchange procedure at Middlemore Hospital, New Zealand

Yvonne YL Lee (Health Economic and Market Access, Terumo BCT Asia, Singapore)



10:45-12:00 Japanese Oral 3 — Collagen Disease/Rheumatology/others

Chair: Takuya Nemoto (*Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Japan*)

- JO3-01 Plasma exchange in 3 patients with antiphospholipid syndrome**
- JO3-02 Effectiveness of combined therapy of PSL+IVCY+DFPP for skin sclerosis in patients with diffuse cutaneous systemic sclerosis**
- JO3-03 Six cases of anti MDA-5 antibody positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with plasmapheresis**
- JO3-04 Apheresis for Immune-related adverse events of immune checkpoint inhibitors**
- JO3-05 In the case of thrombotic microangiopathy treated by simple plasma exchange with albumin as the replacement solution**

14:00-15:30 English Oral 3 — Collagen Disease/Rheumatology/others

Chair: Makio Kusaoi (*Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Japan*)

- EO3-01 Prognosis of anti-MDA5 antibody positive clinically amyopathic dermatomyositis treated with plasma exchange; a case series of single center experience**
Satoshi Kumakura (*Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University, Sendai, Japan*)
- EO3-02 Case series: Successful treatment of Adult Onset Still's Disease (AOSD) using Plasma Exchange**
Fumika Homma (*Division of Nephrology, Department of Internal Medicine, Teikyo University, Tokyo, Japan*)
- EO3-04 The economic impact of centrifugal technique for therapeutic plasma exchange; public hospital perspective**
Yvonne YL Lee (*Hematology Department, National Cheng Kung University Hospital, Taiwan*)
- EO3-05 Effectiveness of Therapeutic Plasma Exchange in the Treatment of Catastrophic Antiphospholipid Syndrome: A 15-year Retrospective Review**
Dobri Kiprof (*Department of Medicine, California Pacific Medical Center, San Francisco, California, USA*)
- EO3-06 The efficacy of plasmapheresis for multiple sclerosis and neuromyelitis optica unresponsive to steroid-pulse therapy and its immunological prognostic markers**
Youwei Lin (*Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan*)



15:30-16:30 State of the Art 4 — Hepatology

Chair: Kyou-Sup Han *(Medical Director of the Blood Bank, Seoul National University Hospital, Korea)*

SA4-01 Artificial liver treatment improves survival in patients with acute-on-chronic liver failure: A prope

Lingling Yang *(State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China)*

SA4-02 1,5-Anhydroglucitol predicts proliferation of liver parenchymal cells during liver regeneration

Yalei Zhao *(State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China)*

SA4-03 Transcriptomics identifies immune-metabolism disorder in development and progression of hepatitis B virus-related acute-on-chronic liver failure

Jun Li *(State Key Laboratory for Diagnosis and Treatment of Infectious Diseases The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China)*

SA4-04 Aristolochic Acid I induced FLAP/CysLTs/CYLD signaling axis in premalignant liver tissue

Kunkai Su *(State Key Laboratory and National Clinical Research Center for Infectious Diseases, 1st Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China)*

Room E

9:00-10:30 Japanese Oral 4 — Technology 1

Chair: Atsushi Ohkubo *(ME Center, Tokyo Medical and dental University Hospital, Japan)*

JO4-01 Seeking for a possibility of innovative apheresis for reduction in task load of patients

JO4-02 Changes in granulocyte adhesion of Adacolumn cellulose acetate beads during GMA treatment

JO4-03 The usefulness of acquiring access with puncture under shunt map andecho guidance for GMA therapy

JO4-04 Study of session time and adsorption efficiency in GMA using single needle method

JO4-05 The effect of double-filtration plasmapheresis thermo-mode(DFT) on hemodialysis patients complicated with peripheral artery disease(PAD)

JO4-06 Survey of adverse events and measures for apheresis therapy

Program
Friday, Oct.
18, 2019

Program
Saturday, Oct.
19, 2019

Program
Sunday, Oct.
20, 2019

Special Lecture

Symposium

Guideline
Session

Apheresis
Manual Lecture

Technical Talk

E-SFA
Work Shop

State of the Art
in the World

English
Oral Session

Japanese
Oral Session

Poster
Presentation

Sponsored
Seminar



10:45-12:15 Japanese Oral 5 — Technology 2/others

Chair: Hitomi Iwamoto (*Tenjinkai Social Medical Corporation, Japan*)

- JO5-01 Relationship between replacement rate of albumin solution/fresh frozen plasma combination and changes of plasma fibrinogen levels in plasma exchange
- JO5-02 Clinical use of a solute kinetics simulation method for double filtration plasmapheresis
- JO5-03 Comparing centrifugal and membrane therapeutic plasma exchange procedures in Japan
- JO5-04 A case report of low-density lipoprotein apheresis using centrifugal separation and dextran sulphate adsorption
- JO5-05 A comparative study of double filtration plasma exchange and selective plasma exchange in ABO blood group incompatible kidney transplantation

13:40-15:10 Japanese Oral 6 — Nephrology/Transplantation

Chair: Tsukasa Nakamura (*Shinmatsudo Central general Hospital, Japan*)

- JO6-02 A case of thrombotic microangiopathy, successfully treated with plasma exchange
- JO6-03 Complete remission of steroid-resistant minimal-change nephrotic syndrome by the treatment with a combination of LDL-apheresis and cyclosporin
- JO6-04 Comparison study of AcuFil Multi 55X-II dedicated circuit SHG-1.0 (PS) and Prismaflex HFset (PAES)
- JO6-05 Preoperative LDL apheresis in renal transplantation for FSGS
- JO6-06 Adverse effects during plasma exchange of donor specific anti-HLA antibody positive kidney transplantation in a patient

15:30-17:00 Technical Talk 1

Chair: Hitomi Iwamoto (*Tenjinkai Social Medical Corporation, Japan*)

- TT1-01 Therapeutic plasma exchange
- TT1-02 Therapeutic double filtration plasmapheresis

Room D Foyer

10:30-11:40 Poster Presentation 3 — Technology

Chair: Motoyoshi Sato (*Shinshiro Municipal Hospital, Japan*)

- PP3-03 Utilization of the newly established dialysis training system using magnetic particles for apheresis training



- PP3-04 **Retrospective comparison and examination about difference of collection method in Autologous Peripheral Blood Stem Cell Collection (APBSCC)**
- PP3-05 **Our experiences with plasm apheresis therapy from 2008 to 2018**
- PP3-06 **Long-term results of treatment for critical limb ischemia in maintenance dialysis patients**
- PP3-07 **The Education Method in Apheresis in The Clinical Engineering Technical Training School of Japan**

15:00-16:10 **Poster Presentation 4 — Neurology/Rare disease/Nursing**

Chair: Katsuchi Miyamoto (*Faculty of Medical Science, Kindai University, Japan*)

- PP4-01 **Red cell exchange verse blood transfusion therapy: improving patient outcomes**
Samantha Easton (*Mater Cancer Care Centre, Mater Health Services, South Brisbane, Queensland, Australia*)
- PP4-02 **Successful Treatment with Early Plasmapheresis in Secondary Hemophagocytic Lymphohistiocytosis(HLH) with Cytomegalovirus Infection in Myasthenia Gravis**
Kuan-Yu Lin (*Department of Neurology, Shin Kong WHS Memorial Hospital, Taipei, Taiwan*)
- PP4-03 **Treatment of Stiff-person syndrome using double filtration plasmapheresis and immunoabsorption**
Sergei Bardakov (*Department of Nephrology and Extracorporeal haemocorrection of Medical Military Academy, St.Petersburg, Russia*)
- PP4-04 **Plasma Exchange to Myopathy without Optic Neuritis or Quadriplegia in Neuromyelitis Optica Spectrum Disorders: A Case Report**
Yoshito Yamaguchi (*Division of Nephrology, Department of Internal Medicine, Otemae Hospital, Japan*)
- PP4-05 **Efficacy of plasmapheresis for patients with stiff person syndrome. Summary of case-study reports**
Akihito Tanaka (*Division of Nephrology, Nagoya University Hospital, Nagoya, Japan*)
- PP4-06 **A case of relapsing acquired thrombotic thrombocytopenic purpura successfully treated with simple plasma exchange and rituximab combination therapy**
- PP4-07 **Efficacy of plasmapheresis for autoimmune limbic encephalitis**

Program
Friday, Oct.
18, 2019

Program
Saturday, Oct.
19, 2019

Program
Sunday, Oct.
20, 2019

Special Lecture

Symposium

Guideline
Session

Apheresis
Manual Lecture

Technical Talk

E-ISFA
Work Shop

State of the Art
in the World


English
Oral Session

Japanese
Oral Session

Poster
Presentation

Sponsored
Seminar





Program

Sunday, October 20, 2019

Program
Friday, Oct.
18, 2019

Program
Saturday, Oct.
19, 2019

Program
Sunday, Oct.
20, 2019

Special Lecture

Symposium

Guideline
Session

Apheresis
Manual Lecture

Technical Talk

E-ISFA
Work Shop

State of the Art
in the World

English
Oral Session

Japanese
Oral Session

Poster
Presentation

Sponsored
Seminar

Oct 20th Room A

9:00-10:30 Symposium 16 — Vasculitis

Apheresis for various vasculitis

Chairs: Wladimir Szpirt (*Rigshospitale, Copenhagen, Denmark*)
 Shoichi Fujimoto (*Faculty of Medicine, University of Miyazaki, Japan*)

SY16-01 Therapeutic apheresis for cryoglobulinemic vasculitis in Japan

Yuri Ishizaki (*Division of Nephrology, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan*)

SY16-02 Extracorporeal Treatment Measures in Immune-Complex Small-Vessel Vasculitides

Andreas Kronbichler (*Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Austria*)

SY16-03 Plasma exchange therapy to reduce mortality in Japanese patients with microscopic polyangiitis, particularly diffuse alveolar hemorrhage

Yoshiyuki Abe (*Department of Internal Medicine and Rheumatology, Juntendo University, Tokyo, Japan*)

SY16-04 Should we still plasma exchange in Vasculitis based on Pexivas results?

Wladimir Szpirt (*Rigshospitale, Copenhagen, Denmark*)

10:45-12:15 Symposium 17 — LDL

Lipoprotein Apheresis in Kidney Disease

Chairs: Eri Muso (*Department of Food and Nutrition, Faculty of Home Economics, Kyoto Kacho University, Japan*)
 Takashi Wada (*Department of Nephrology and Laboratory Medicine University, Japan*)

SY17-01 Canceled**SY17-02 Lipoprotein apheresis for kidney disease in adult**

Norihiko Sakai (*Division of Blood Purification, Kanazawa University Hospital, Kanazawa, Japan*)

SY17-03 Lipoprotein apheresis for kidney disease in children in US

Katherine Twombly (*Pediatrics, Medical University of South Carolina, USA*)

SY17-04 Lipoprotein apheresis for kidney disease in children in Japan

Naoto Kaneko (*Department of Pediatric Nephrology, Tokyo Women's Medical University, Tokyo, Japan*)

12:30-13:30 Luncheon Seminar 7

Sponsored by NIPRO

Technical issues with continuous renal replacement therapy management

Chair: Yutaka Eguchi (*Department of Critical and Intensive Care Medicine, Shiga University of Medical Science Shiga, Japan*)

LS7-01 Technical issues with continuous renal replacement therapy management

Kunihiko Kooguchi (*Critical care department, Kyoto City Hospital, Japan*)


13:40-15:10 Symposium 18 — Pediatrics
Applications and Effectiveness of Apheresis Therapy for Severe Conditions in Children

Chairs: Chisa Yamada (*Department of Pathology, University of Michigan, USA*)
 Masaaki Mori (*Lifetime Clinical Immunology, Tokyo Medical and Dental University, Japan*)

SY18-01 Hemolytic uremic syndrome in pediatric patients

Akira Ashida (*Department of Pediatrics, Osaka Medical College, Japan*)

SY18-02 Plasma exchange therapy for cases refractory to IVIG treatment in Kawasaki disease in Japan

Masaaki Mori (*Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan*)

SY18-03 Plasma exchange and chelator therapy rescues acute liver failure in Wilson disease without liver transplantation: Form our experiences

Jun Kido (*Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University, Japan*)

SY18-04 Therapeutic Plasma Exchange Treatment for Wilson's Disease in the USA

Chisa Yamada (*Transfusion Medicine, Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA*)

15:30-16:30 State of the Art 5 — State of the Art in the World

Chair: Yoshihiro Endo (*Department of Clinical Nursing, Shiga University of Medical Science, Japan*)

SA5-01 Neuro-Apheresis: From stroke to Alzheimer's Disease

Juergen Graessler (*Third Department of Internal Medicine, University Hospital Carl Gustav Carus, Dresden, Germany*)

SA5-02 Long-term lipoprotein apheresis: effects on natriuretic peptides, PCSK9, and immunological parameters

Juergen Graessler (*Department and Outpatient Department of Medicine III, University Hospital at the Technische Universitaet Dresden, Germany*)

SA5-03 A Nationwide Population Based Study of Therapeutic Plasma Exchange for 10 years in Korea

Jae Hyeon Park (*Department of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea*)

SA5-04 The Challenges of Placebo Controlled Clinical Trials in Therapeutic Apheresis

Dobri Kiproff (*Apheresis Care Group, California Pacific Medical Center, Global Apheresis, San Francisco, CA, USA*)

 Program
 Friday, Oct.
 18, 2019

 Program
 Saturday, Oct.
 19, 2019

 Program
 Sunday, Oct.
 20, 2019

Special Lecture

Symposium

 Guideline
 Session

 Apheresis
 Manual Lecture

Technical Talk

 E-SFA
 Work Shop

 State of the Art
 in the World

 English
 Oral Session

 Japanese
 Oral Session

 Poster
 Presentation

 Sponsored
 Seminar


Room D

9:00-10:00 English Oral 4 — IBD/Ascites/CART/Technology

Chair: Tatsuo Tsukamoto (*Department of Nephrology and Dialysis, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Japan*)

EO4-01 Treatment result of the curative effect of GCAP for the intractable UC in our Hospital (examination about the blood throughput)

Katsuji Otsuka (*Kumamoto University Hospital, Japan*)

EO4-02 Modification of the Dialysate Port of Plasma Separator; A measure against mix-up of plasma separator with hemofilter (final report)

Tatsuo Tsukamoto (*Department of Nephrology and Dialysis, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Japan*)

EO4-03 Cell-Free and Concentrated Ascites Reinfusion Therapy against refractory ascites on various disease

Masahiro Hattori (*The Department of Surgery, Sapporo Hokuyu hospital, Sapporo, Japan*)

EO4-04 Assessing cost of membrane and centrifugal techniques for therapeutic plasma exchange in Thailand

Srisawat Nattachai (*Nephrology Department, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand*)

10:45-12:15 Symposium 19 — Canceled

13:40-15:10 Symposium 20 — Collagen Disease/Rheumatology

Therapeutic apheresis for rheumatic diseases

Chair: Ken Yamaji (*Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Japan*)

SY20-01 Plasma Exchange and Immunoabsorption in Connective Tissue Diseases

Andreas Kronbichler (*Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Austria*)

SY20-02 Extracorporeal Treatment in Systemic Lupus Erythematosus

Katharina Artinger (*Division of Nephrology, Department of Internal Medicine Graz, Austria*)

SY20-03 The improvement of severe systemic lupus erythematosus with the combined Plasmapheresis and immunosuppressive treatment: a cohort review

Sanxi Ai (*The Kidney Division of Peking Union Medical College Hospital, Beijing, China*)

SY20-04 Therapeutic apheresis for anti-melanoma differentiation-associated gene 5 antibody-positive inflammatory myositis associated rapidly progressive interstitial lung disease

Makio Kusaoi (*Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan*)

SY20-05 Efficacy of Plasma Exchange and Prognostic Factors in Anti-MDA5 Antibody-positive Dermatomyositis with Interstitial Lung Disease

Ran Nakashima (*Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Japan*)


15:30-16:15 English Oral 5 — Dermatology/Neurology

- Chairs:** Mariko Seishima (*Department of Dermatology, Gifu University Graduate School of Medicine, Japan*)
 Katsuchi Miyamoto (*Kindai University Faculty of Medicine, Japan*)

E05-01 A case of pustular psoriasis deteriorated during the second pregnancy was successfully treated with intensive GMA and certolizumab pegol

Asumi Fujii (*Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan*)

E05-02 Plasma Exchange in Neuromyelitis Optic Spectrum Disorders

Camilo Gonzalez (*Nephrology unit of internal medicine department, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogota, Colombia*)

E05-03 Efficacy of intravenous methylpredonisolon and plasmapheresis in relapsing MOG-IgG+disease: early institution of plasmapheresis

Satoru Oji (*Department of Neurology, Saitama Medical Center, Saitama Medical University, Japan*)

Room B-1
9:00-10:00 Japanese Oral 7 — Hematology/PAD

- Chair:** Shuichi Ota (*Sapporo Hokuyu Hospital, Japan*)

JO7-01 Analysis of the effect of LDL-A on leg ulcers
JO7-02 Successful plasmaexchange(PE) for ABO-incompatible liver transplantation in a 2-year-old child with peliosis hepatis and myotubular myopathy
JO7-03 A case of Goodpasture syndrome successfully treated with continuous plasma exchange with dialysis
JO7-04 Peripheral blood stem cell harvest based on the number of CD34 positive cells in peripheral blood
**10:45-12:15 State of the Art 6 —
Neurology/Dermatology/Critical Care Medicine**

- Chair:** Flora Sandra Siami (*Clinical Research, HealthCore NERI, USA*)

SA6-01 Our Achievement In Establishment Of In-house Neurology Driven Therapeutic Plasma Exchange (TPE) Infrastructure In A Resource-Limited Public Hospital In Malaysia

Shirley Lee (*Neurology Department, Kuala Lumpur Hospital, Malaysia*)

SA6-02 Establishment of South East Asia Regional Neurological Disorders Therapeutic Plasma Exchange Consortium

Sing Keat Wong (*Department of Neurology, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia*)

 Program
Friday, Oct.
18, 2019

 Program
Saturday, Oct.
19, 2019

 Program
Sunday, Oct.
20, 2019

Special Lecture

Symposium

 Guideline
Session

 Apheresis
Manual Lecture

Technical Talk

 E-ISFA
Work Shop

 State of the Art
in the World

 English
Oral Session

 Japanese
Oral Session

 Poster
Presentation

 Sponsored
Seminar


SA6-03 MicroRNA and granulocyte and monocyte adsorption apheresis on neutrophilic skin diseases

Yuko Higashi *(Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima University, Sakuragaoka, Kagoshima, Japan)*

SA6-04 The use of therapeutic plasma exchange in clinical settings: an economic evaluation in a single institution in China

Yvonne YL Lee *(Hematology Department, Longyan First Municipal Hospital, Fujian, China)*

SA6-05 Cost savings with centrifugal therapeutic plasma exchange in intensive care unit Vietnam

Yvonne YL Lee *(Intensive Care Unit, Ho Chi Minh City Hospital, Vietnam)*

SA6-06 The 5-year Experiences and Outcomes in Plasmapheresis of non-Transplantation Patients in Limited-Resource Center of Thailand

Wanjak Pongsittisak *(Renal Division, Department of Medicine, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand)*

13:40-15:10 Symposium 21 — Hepatology 1

Role of apheresis therapy in liver failure 1

Chairs: Lanjuan Li *(School of Medicine, Zhejiang University, China)*
Kazuaki Inoue *(Gastroenterology, Showa University Fujigaoka Hospital, Japan)*

SY21-01 Advancement in Liver Failure and Artificial Liver

Lanjuan Li *(State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou, China)*

SY21-02 Extracorporeal Liver Support (ELS) in acute and acute on chronic Liver Failure

Jan Stange *(Department of Medicine, University of Rostock, Rostock, Germany)*

SY21-03 High-volume filtrate hemodiafiltration improves recovery rate from hepatic encephalopathy in acute liver failure patients

Ryuzo Abe *(Department of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba, Japan)*

SY21-04 Continuous Plasma Exchange with Dialysis for Patient with Acute Liver Failure

Kasumi Satoh *(Emergency and Critical Care Medicine, Akita University Graduate School of Medicine, Japan)*

15:30-16:30 Symposium 22 — Hepatology 2

Role of apheresis therapy in liver failure 2

Chair: Kazuaki Inoue *(Gastroenterology, Showa University Fujigaoka Hospital, Japan)*

SY22-01 A referral system and an artificial liver support system as intensive care for patients with acute liver failure

Keisuke Kakisaka *(Division of Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan)*

SY22-03 Overview of artificial liver support in Japan

Kazuaki Inoue *(Showa University Fujigaoka Hospital Division of Gastroenterology, Japan)*



Room B-2

9:00-10:00 Symposium 23 — Neurology 1

Recent advance in TPE for neurological disorders 1

Chairs: Hou-Chang Chiu (*Fu-Jen Catholic University Hospital, Taiwan*)
 Hidenori Matsuo (*National Hospital Organization, Nagasaki National Hospital, Japan*)

SY23-01 Japan-Plasmapheresis Outcome and Practice Patterns Study (J-POPPS) for Neurological diseases: A multi-center real world survey

Youwei Lin (*National Center of Neurology and Psychiatry, Japan*)

SY23-02 Therapeutic Plasma Exchange in Neurological Disorders

Naraporn Prayoonwiwa (*Division of Neurology, Department of Medicine, Faculty of Medicine, Siriraj Hospital Mahidol University, Thailand*)

SY23-03 Plasmapheresis in Autoimmune Encephalitis

Mei-Yun Cheng (*Chang Gung Memorial Hospital, Taipei, Taiwan*)

10:45-11:45 Symposium 24 — Neurology 2

Recent advance in TPE for neurological disorders 2

Chairs: Hou-Chang Chiu (*Fu-Jen Catholic University Hospital, Taiwan*)
 Hidenori Matsuo (*National Hospital Organization, Nagasaki National Hospital, Japan*)

SY24-01 Apheresis treatment to autoimmune disorders in central nervous system: Therapeutic strategy in relapsing NMOSD and MOG-IgG+disease

Satoru Oji (*Department of Neurology, Saitama Medical Center, Saitama Medical University, Japan*)

SY24-02 Plasmapheresis in patients with dual diagnosis of myasthenia gravis and neuromyelitis optica spectrum disorder

Jiann-Horng Yeh (*Department of Neurology, Shin Kong WHS Memorial Hospital, Taipei, Taiwan*)

SY24-03 Apheresis for immune neuropathy: Proper use with IVIG

Katsuichi Miyamoto (*Department of Neurology, Kindai University School of Medicine, Osaka, Japan*)

13:40-14:40 English Oral 6 — Neoplasm /Cardiology/Nephrology

Chair: Tomoharu Shimizu (*Department of Surgery, Shiga University of Medical Science, Japan*)

EO6-01 The application of the adsorbent for LAP positive T cells to cancer therapy

Kazuo Teramoto (*Dept. of Pathology, Shiga University of Medical Science, Japan*)

EO6-02 Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer

Masahiro Ogasawara (*Department of Internal Medicine, Sapporo Hokuyu Hospital, Sapporo, Japan*)

EO6-03 Apheresis treatment for refractory nephrotic syndrome by focal segmental glomerulosclerosis; A systematic review of published cases

Tatsuo Tsukamoto (*Department of Nephrology and Dialysis, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan*)

Program
Friday, Oct.
18, 2019

Program
Saturday, Oct.
19, 2019

Program
Sunday, Oct.
20, 2019

Special Lecture

Symposium

Guideline
Session

Apheresis
Manual Lecture

Technical Talk

E-ISFA
Work Shop

State of the Art
in the World

English
Oral Session

Japanese
Oral Session

Poster
Presentation

Sponsored
Seminar



15:30-16:30 Japanese Oral 8 — Critical Care Medicine/Pediatrics

Chairs: Hidetoshi Shiga (*Teikyo University Chiba Medical Center, Japan*)
Akira Ashida (*Department of Pediatrics, Osaka Medical College, Japan*)

- JO8-01 Experience of plasmapheresis in our intensive care unit for 4 years**
JO8-02 Study of acute poisoning cases treated with direct hemoperfusion in ICU
JO8-03 Successful treatment with cyclosporine for infant with Kawasaki disease refractory to both Infiximab and plasma exchange: a case report
JO8-04 Efficacy and safety of selective plasma exchange in children

Room E

9:00-10:30 Technical Talk 2

Chair: Atsushi Ohkubo (*ME center, Tokyo Medical and dental University Hospital, Japan*)

- TT2-03 The safety and efficacy of selective plasma exchange**
TT2-04 Immunoadsorption in Japan

10:45-12:15 Technical Talk 3

Chair: Yoshie Tokui (*Tokyo Women's Medical University Hospital, Japan*)

- TT3-05 Therapeutic Leukocytapheresis**
TT3-06 CART (cell-free and concentrated ascites reinfusion therapy)

13:40-15:10 Technical Talk 4

Chair: Atsushi Ohkubo (*ME center, Tokyo Medical and dental University Hospital, Japan*)

- TT4-07 Continuous blood purification (CBP) / Endotoxin adsorption therapy**
TT4-08 LDL adsorption therapy

15:30-16:15 Japanese Oral 9 — Technology 3

Chair: Hitomi Iwamoto (*Tenjinkai Social Medical Corporation, Japan*)

- JO9-01 The oncotic pressure and electrolyte composition in the various albumin solutions as replacement fluids of plasma exchange**
JO9-02 Therapeutic effect of selective plasma exchange in Jichi Medical University
JO9-03 An example in which securing blood access by echo utilization was effective in CAP therapy



Room D Foyer

10:30-11:40

Poster Presentation 5 — Nephrology/Collagen/Disease/Rheumatology

Chair: Maki Kagitani *(Blood Purification Center, Osaka Medical College Hospital, Japan)*

PP5-01 Long-term Ig apheresis in the treatment of lupus nephritis

Alexey A. Sokolov *(The Department of Nephrology and Extracorporeal haemocorrection of Medical Military Academy, St.Petersburg, Russia)*

PP5-02 Pleiotropic effects of double filtration plasmapheresis in the prevention of in-stent restenosis in patients with stable coronary artery disease

Valery V. Tishko *(The Department of Nephrology and Extracorporeal haemocorrection of Medical Military Academy, St.Petersburg, Russia)*

PP5-04 Low-density Lipoprotein Apheresis in Patients with Acute Kidney Injury due to Minimal Change Disease requiring Acute Renal Replacement Therapy

Kohsuke Terada *(Department of Nephrology, Nippon Medical School, Tokyo, Japan)*

PP5-05 A case of atypical hemolytic uremic syndrome, which steroid pulse therapy and plasma exchange were effective but eculizumab was ineffective

PP5-06 A case in which cryofiltration was useful for cryoglobulin angiitis complicated with intractable systemic lupus erythematosus

PP5-07 Successful treatment of LDL-A for skin ulcers in a patient with systemic sclerosis

15:00-16:00 Poster Presentation 6 — Critical Care Medicine

Chair: Tomoharu Shimizu *(Department of Surgery, Shiga University of Medical Science, Japan)*

PP6-01 LPS adsorption with Toxipak columns in treatment of sepsis

Alexey A. Sokolov *(The Department of Anesthesiology and Reanimatology, North-Western State Medical University named after I.I.Mechnikov, St.Petersburg, Russia)*

PP6-04 Three cases of acute pancreatitis due to Hypertriglyceridemia treated with PE and HD

PP6-05 Blood purification in patients with sepsis

PP6-06 Clinical study of pressure difference between membranes and effective period of use of membranes with continuous hemodiafiltration therapy for sepsis

Program
Friday, Oct.
18, 2019

Program
Saturday, Oct.
19, 2019

Program
Sunday, Oct.
20, 2019

Special Lecture

Symposium

Guideline
Session

Apheresis
Manual Lecture

Technical Talk

E-ISFA
Work Shop

State of the Art
in the World

English
Oral Session

Japanese
Oral Session

Poster
Presentation

Sponsored
Seminar

